Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Small cell lung cancer PDX model response to LSD1 inhibitor RG6016/ORY1001

ABSTRACT: This SuperSeries is composed of the SubSeries listed below.

ORGANISM(S): Homo sapiens

PROVIDER: GSE103097 | GEO | 2019/06/10

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Comparison of small cell lung cancer PDX model FHSC04 for response to LSD1 inhibitor RG6016/ORY1001

Project description:The goal of this study was to understand how the LSD1 inhibitor RG6016/ORY1001 leads to selective efficacy in subsets of small cell lung cancer. SCLC cell lines, PDX models studied ex vivo and studied in vivo were employed in this analysis

2019-06-10 | GSE103096 | GEO

Small cell lung cancer PDX model response to LSD1 inhibitor RG6016/ORY1001

Project description:Small cell lung cancer PDX model response to LSD1 inhibitor RG6016/ORY1001

| PRJNA400180 | ENA

Targeting P4HA1 with a Small Molecule Inhibitor in a Colorectal Cancer PDX Model.

Project description:Deposition, remodeling, and signaling of the extracellular matrix facilitate tumor growth and metastasis. Here, we demonstrated that an enzyme, collagen prolyl 4-hydroxylase, alpha polypeptide I (P4HA1), which is involved in collagen synthesis and deposition, had elevated expression in colorectal cancers (CRCs) as compared to normal colonic tissues. The expression of P4HA1 in CRCs was independent of patient's age, race/ethnicity, gender, pathologic stage and grade, tumor location, and microsatellite instability (MSI) and p53 status. By modulating P4HA1 with shRNA, there was a reduction in malignant phenotypes of CRCs, including cell proliferation, colony formation, invasion, migration, and tumor growth, in mice regardless of their p53 and MSI status. Immunoblot analysis of excised xenograft tumors developed from cells with silenced PH4HA1 showed low levels of proliferating cell nuclear antigen. Further, in CRC mouse models, silencing of P4HA1 in HT29 cells resulted in less metastasis to liver and bone. P4HA1 expression was regulated by miR-124, and inhibition of cell growth was noted for CRC cells treated with miR-124. Furthermore, low levels of the transcriptional repressor EZH2 reduced P4HA1 expression in CRC cells. Inhibition of P4HA1 with the small molecule inhibitor diethyl-pythiDC decreased AGO2 and MMP1, which are P4HA1 target molecules, and reduced the malignant phenotypes of CRC cells. Treatment of CRC patient-derived xenografts that exhibit high expression of P4HA1 with diethyl-pythiDC resulted in tumor regression. Thus, the present study shows that P4HA1 contributes to CRC progression and metastasis and that targeting of P4HA1 with diethyl-pythiDC could be an effective therapeutic strategy for aggressive CRCs.

| S-EPMC7082635 | biostudies-literature

Comparison of 7 small cell lung cancer PDX models, cultured ex vivo, for response to LSD1 inhibitor RG6016/ORY1001

2019-06-10 | GSE103095 | GEO

Targeting Transcriptional Addictions in Small Cell Lung Cancer with a Covalent CDK7 Inhibitor

Project description:This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

2014-10-23 | E-GEOD-62614 | biostudies-arrayexpress

LSD1/KDM1 isoform LSD1+8a contributes to neural differentiation in small cell lung cancer.

Project description:Small cell lung cancer (SCLC) is an aggressive neuroendocrine tumor characterized by rapid progression. The mechanisms that lead to a shift from initial therapeutic sensitivity to ultimate therapeutic resistance are poorly understood. Although the SCLC genomic landscape led to the discovery of promising agents targeting genetic alterations that were already under investigation, results have been disappointing. Achievements in targeted therapeutics have not been observed for over 30 years. Therefore, the underlying disease biology and novel targets urgently require a better understanding. Epigenetic regulation is deeply involved in the cellular plasticity that could shift tumor cells to the malignant phenotype. We have focused on a histone modifier, LSD1, that is overexpressed in SCLC and is a potent therapeutic target. Interestingly, the LSD1 splice variant LSD1+8a, the expression of which has been reported to be restricted to neural tissue, was detected and was involved in the expression of neuroendocrine marker genes in SCLC cell lines. Cells with high expression of LSD1+8a were resistant to CDDP and LSD1 inhibitor. Moreover, suppression of LSD1+8a inhibited cell proliferation, indicating that LSD1+8a could play a critical role in SCLC. These findings suggest that LSD1+8a should be considered a novel therapeutic target in SCLC.

| S-EPMC5614583 | biostudies-literature

Targeting Transcriptional Addictions in Small Cell Lung Cancer with a Covalent CDK7 Inhibitor

Project description:This SuperSeries is composed of the SubSeries listed below.

2014-10-23 | GSE62614 | GEO

Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition.

Project description:Small cell lung cancer (SCLC) is a recalcitrant, aggressive neuroendocrine-type cancer for which little change to first-line standard-of-care treatment has occurred within the last few decades. Unlike nonsmall cell lung cancer (NSCLC), SCLC harbors few actionable mutations for therapeutic intervention. Lysine-specific histone demethylase 1A (LSD1 also known as KDM1A) inhibitors were previously shown to have selective activity in SCLC models, but the underlying mechanism was elusive. Here, we found that exposure to the selective LSD1 inhibitor ORY-1001 activated the NOTCH pathway, resulting in the suppression of the transcription factor ASCL1 and the repression of SCLC tumorigenesis. Our analyses revealed that LSD1 bound to the NOTCH1 locus, thereby suppressing NOTCH1 expression and downstream signaling. Reactivation of NOTCH signaling with the LSD1 inhibitor reduced the expression of ASCL1 and neuroendocrine cell lineage genes. Knockdown studies confirmed the pharmacological inhibitor-based results. In vivo, sensitivity to LSD1 inhibition in SCLC patient-derived xenograft (PDX) models correlated with the extent of consequential NOTCH pathway activation and repression of a neuroendocrine phenotype. Complete and durable tumor regression occurred with ORY-1001-induced NOTCH activation in a chemoresistant PDX model. Our findings reveal how LSD1 inhibitors function in this tumor and support their potential as a new and targeted therapy for SCLC.

| S-EPMC6530478 | biostudies-literature

Small cell lung cancer

Project description:This SuperSeries is composed of the SubSeries listed below.

2021-12-01 | GSE160241 | GEO

LSD1 promotes castration-resistant prostate cancer progression

Project description:This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

2016-06-30 | E-GEOD-77763 | biostudies-arrayexpress